Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Registration and characterization of patients with Glucose-6-Phosphate Dehydrogenase Deficiency in Spain: A real-world study of the Spanish Erythropathology Group (GEE)

Blood (2025) 146 (Supplement 1): 4723.

https://doi.org/10.1182/blood-2025-4723

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Talquetamab outcomes from practice outside of clinical trials: The bital study

María-Victoria Mateos, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Jesús Blanchard, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2025-5827

Published: 2025

Journal Articles

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Roberto Mancebo-Martin, Magdalena Corona De Lapuerta, Lara Rodriguez-Luque, Cristian Gutiérrez Padilla, David Bermejo-Peláez, Nuria Diez Navarro, David Brau-Queralt, Nieves Lopez Muñoz, Rafael Alonso Fernandez, Jose Maria Sanchez Pina, Miguel Luengo-Oroz, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 6349.

https://doi.org/10.1182/blood-2025-6349

Published: 2025

Journal Articles

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Maria Sanchez-Tabernero, Magdalena Corona, Cristian Gutiérrez Padilla, Jose Sanchez-Pina, Rafael Alonso, Inmaculada Rapado, Nieves Lopez-Muñoz, Gonzalo Carreño, Susana Cortijo, Maria Teresa Cedena Romero, Manuela Fernández, Rosa Ayala Diaz, Maria Calbacho, Joaquin Martinez-Lopez

Blood (2025) 146 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2025-5781

Published: 2025

Journal Articles

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

María-Jesús Blanchard, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Victoria Mateos, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2025-2272

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients

Blood (2025) 146 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2025-3785

Published: 2025

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Almudena Cabero Martínez, Ana García Bacelar, Begoña Mendibil Esquisabel, Javier Nuñez Cespedes, Ana Jiménez Ubieto, Eukene Gainza Gonzalez, Elena Perez Ceballos, Beatriz De La Cruz, Ana Garcia Noblejas, Paula Fernández-Caldas, Norma C. Gutierrez, Blanca Sánchez-González, Rocío Figueroa Mora, Alberto Lopez Garcia, Daniel García Belmonte, Maria Sanchez de Castro, Estefania Cerezo Velasco, Xabier Martin Martitegui, Hugo Daniel Luzardo Henríquez, Jordina Rovira, Luis Antonio Lopez Gomez, Jackeline Solano, Ana Torres Tienza, Maria Stefania Infante, Raquel Santiago Alonso, Raquel Del Campo, Dunia De Miguel Llorente, Alicia Roldán-Pérez, Emilia Pardal, Beatriz Gonzalez Mena, Miguel Ángel Rodríguez Gil, Nazaret Domínguez Velasco, Albert Blanco Juan, Maria Alejandra Blum Dominguez, Javier López Marin, María Peñarrubia-Ponce, Mariana Bastos-Oreiro, Alejandro Martín García-Sancho

Blood (2024) 144 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2024-198904

Published: 2024

Journal Articles

Avatrombopag Use in Patients with Persistent Thrombocytopenia Secondary to Intensive Chemotherapy Treatment

Aser Alonso Carballo, Marta Lopez Lopez-Cepero, Maria Jimenez Moya, Sandra Pérez, Lucia García Mañó, Jose Maria Sanchez Raga, Aina Oliver Caldes, Leyre Bento De Miguel, Andres Novo Garcia, Guiomar Puget Juan, Bernat Galmes Sureda, Antonio Palomero Massanet, Carlos Fernández de Larrea, Antonia Sampol Mayol, Mariana Canaro Hinryk

Blood (2024) 144 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2024-210402

Published: 2024

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6087.

https://doi.org/10.1182/blood-2023-187057

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 267.

https://doi.org/10.1182/blood-2023-186388

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Blood (2023) 142 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2023-181815

Published: 2023

Journal Articles

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Adolfo Jesús Sáez Marín, Gema Hernández-Ibarburu, Rafael Alonso Fernández, Jose Maria Sanchez Pina, Paula Lázaro Del Campo, Ana Jimenez Ubieto, Clara Cuellar, Andrea Tamayo Soto, Reyes Mas Babio, Lucia Medina, Maria Calbacho, Rosa Ayala, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2023-180923

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, José María Sanchez-Pina, Serena Rocchi

Blood (2023) 142 (Supplement 1): 6910.

https://doi.org/10.1182/blood-2023-182164

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Registration and characterization of patients with Glucose-6-Phosphate Dehydrogenase Deficiency in Spain: A real-world study of the Spanish Erythropathology Group (GEE)

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Talquetamab outcomes from practice outside of clinical trials: The bital study

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Avatrombopag Use in Patients with Persistent Thrombocytopenia Secondary to Intensive Chemotherapy Treatment

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only